PA
KURA icon

Parallel Advisors’s Kura Oncology KURA Stock Holding History

Parallel Advisors’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.39K Sell
309
-204
-40% -$1.93K ﹤0.01% 3361
2026
Q1 		$4.17K Buy
513
+270
+111% +$2.32K ﹤0.01% 3102
2025
Q4 		$2.52K Hold
243
– – ﹤0.01% 3071
2025
Q3 		$2.15K Sell
243
-398
-62% -$2.84K ﹤0.01% 3028
2025
Q2 		$3.7K Buy
+641
New +$3.93K ﹤0.01% 2849
2025
Q1 		– Sell
-212
Closed -$1.65K – 3602
2024
Q4 		$1.85K Buy
212
+40
+23% +$576 ﹤0.01% 2996
2024
Q3 		$3.36K Hold
172
– – ﹤0.01% 2744
2024
Q2 		$3.54K Buy
+172
New +$3.54K ﹤0.01% 2633
2022
Q3 		– Sell
-11
Closed – – 3339
2022
Q2 		$0 Buy
+11
New +$158 ﹤0.01% 3183
2021
Q3 		– Sell
-11
Closed – – 3172
2021
Q2 		$0 Sell
11
-40
-78% -$993 ﹤0.01% 2993
2021
Q1 		$1K Hold
51
– – ﹤0.01% 2643
2020
Q4 		$2K Sell
51
-86
-63% -$3.02K ﹤0.01% 2319
2020
Q3 		$4K Hold
137
– – ﹤0.01% 2105
2020
Q2 		$2K Buy
+137
New +$1.98K ﹤0.01% 2203

Other funds holding KURA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return

Parallel Advisors's KURA Position: Q2 2026 in Review

Parallel Advisors reduced its Kura Oncology (KURA) stake by 40% in Q2 2026, selling an estimated $1.93K and leaving 309 shares worth $3.39K. The position accounts for ﹤0.01% of the portfolio, ranked #3361.

Parallel Advisors first reported a position in KURA in Q2 2020 and has held it in 14 quarters since. The position peaked at $4.17K in Q1 2026. 221 funds tracked by Wall St. Rank hold KURA as of Q2 2026.

  • Parallel Advisors held 309 shares of Kura Oncology worth $3.39K as of Q2 2026.
  • Parallel Advisors sold 204 Kura Oncology shares in Q2 2026, an estimated $1.93K.
  • Kura Oncology made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #3361 holding.
  • Parallel Advisors first reported a position in Kura Oncology in Q2 2020 and has held it in 14 quarters since.
  • Parallel Advisors's Kura Oncology position peaked at $4.17K in Q1 2026.
  • 221 funds tracked by Wall St. Rank held Kura Oncology as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.